Cancer Science, ISSN 1347-9032, 12/2015, Volume 106, Issue 12, pp. 1714 - 1721
Lenvatinib significantly prolonged progression‐free survival (PFS) versus placebo in patients with radioiodine‐refractory differentiated thyroid cancer...
Japanese patients | thyroid cancer | lenvatinib | progression‐free survival | treatment efficacy | Treatment efficacy | Lenvatinib | Thyroid cancer | Progression-free survival | ANGIOGENESIS | EFFICACY | SAFETY | progression-free survival | SORAFENIB | ANTITUMOR ACTIVITIES | RENAL-CELL CARCINOMA | E7080 | THERAPY | ONCOLOGY | DOUBLE-BLIND | INHIBITOR | Carcinoma - drug therapy | Iodine Radioisotopes | Thyroid Neoplasms - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Carcinoma - mortality | Phenylurea Compounds - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Quinolines - pharmacokinetics | Disease-Free Survival | Asian Continental Ancestry Group | Thyroid Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Quinolines - therapeutic use | Analysis | Oncology, Experimental | Clinical trials | Development and progression | Research | Cancer | Body weight | Metastasis | Survival | Studies | Medical prognosis | Fibroblasts | Population | Safety | Vascular endothelial growth factor | Thyroid | Proteinuria | Tumors | Original
Japanese patients | thyroid cancer | lenvatinib | progression‐free survival | treatment efficacy | Treatment efficacy | Lenvatinib | Thyroid cancer | Progression-free survival | ANGIOGENESIS | EFFICACY | SAFETY | progression-free survival | SORAFENIB | ANTITUMOR ACTIVITIES | RENAL-CELL CARCINOMA | E7080 | THERAPY | ONCOLOGY | DOUBLE-BLIND | INHIBITOR | Carcinoma - drug therapy | Iodine Radioisotopes | Thyroid Neoplasms - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Carcinoma - mortality | Phenylurea Compounds - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Quinolines - pharmacokinetics | Disease-Free Survival | Asian Continental Ancestry Group | Thyroid Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Quinolines - therapeutic use | Analysis | Oncology, Experimental | Clinical trials | Development and progression | Research | Cancer | Body weight | Metastasis | Survival | Studies | Medical prognosis | Fibroblasts | Population | Safety | Vascular endothelial growth factor | Thyroid | Proteinuria | Tumors | Original
Journal Article
International Heart Journal, ISSN 1349-2365, 2018, Volume 59, Issue 2, pp. 427 - 430
A 31-year-old man was admitted to our hospital with atrial tachycardia and cardiogenic shock. He had been diagnosed with hereditary spherocytosis (HS) during...
Heart failure | Cardiogenic shock | Atrial tachycardia | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | IRON-OVERLOAD | Cardiac arrhythmia | Hemochromatosis | Arrhythmia | Coexistence | Congestive heart failure | Patients | Heterozygosity | Tachycardia | Biopsy | Hereditary spherocytosis | Fibrosis | Point mutation | Chelation | HFE protein | Children | Ventricle | Spherocytosis
Heart failure | Cardiogenic shock | Atrial tachycardia | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | IRON-OVERLOAD | Cardiac arrhythmia | Hemochromatosis | Arrhythmia | Coexistence | Congestive heart failure | Patients | Heterozygosity | Tachycardia | Biopsy | Hereditary spherocytosis | Fibrosis | Point mutation | Chelation | HFE protein | Children | Ventricle | Spherocytosis
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2015, Volume 76, Issue 2, pp. 375 - 382
We previously reported that a triplet combination of docetaxel, cisplatin, and S-1 (DCS) is active against metastatic gastric cancer with a very high response...
Medicine & Public Health | Oncology | Cancer Research | Feasibility | Pharmacology/Toxicology | HER2 | Gastric cancer | Trastuzumab | PLUS CISPLATIN | FLUOROURACIL | DOCETAXEL | CHEMOTHERAPY | PHASE-III TRIAL | THERAPY | ONCOLOGY | S-1 | PHARMACOLOGY & PHARMACY | Humans | Middle Aged | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Feasibility Studies | Taxoids - administration & dosage | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Antibodies, Monoclonal, Humanized - administration & dosage | Tegafur - administration & dosage | Adult | Female | Aged | Drug Combinations
Medicine & Public Health | Oncology | Cancer Research | Feasibility | Pharmacology/Toxicology | HER2 | Gastric cancer | Trastuzumab | PLUS CISPLATIN | FLUOROURACIL | DOCETAXEL | CHEMOTHERAPY | PHASE-III TRIAL | THERAPY | ONCOLOGY | S-1 | PHARMACOLOGY & PHARMACY | Humans | Middle Aged | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Cisplatin - administration & dosage | Feasibility Studies | Taxoids - administration & dosage | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Antibodies, Monoclonal, Humanized - administration & dosage | Tegafur - administration & dosage | Adult | Female | Aged | Drug Combinations
Journal Article
European Journal of Cancer, ISSN 0959-8049, 01/2019, Volume 106, pp. 61 - 68
In the phase 3 tudy of ( 7080) nvatinib in ifferentiated ancer of the hyroid (SELECT), lenvatinib significantly improved efficacy outcomes versus placebo in...
Thyroid neoplasms | MeSH terms | Lenvatinib | Disease-free survival | E7080 | ONCOLOGY | INHIBITOR | ANTITUMOR ACTIVITIES | Complications and side effects | Care and treatment | Thyroid cancer | Oncology, Experimental | Analysis | Research | Cancer | Interruption | Iodine radioisotopes | Effectiveness | Toxicity | Iodine 131 | Clinical trials | Cancer therapies | Patients | Impact analysis | Confidence intervals | Refractory materials | Drug therapy | Thyroid
Thyroid neoplasms | MeSH terms | Lenvatinib | Disease-free survival | E7080 | ONCOLOGY | INHIBITOR | ANTITUMOR ACTIVITIES | Complications and side effects | Care and treatment | Thyroid cancer | Oncology, Experimental | Analysis | Research | Cancer | Interruption | Iodine radioisotopes | Effectiveness | Toxicity | Iodine 131 | Clinical trials | Cancer therapies | Patients | Impact analysis | Confidence intervals | Refractory materials | Drug therapy | Thyroid
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2015, Volume 76, Issue 6, pp. 1153 - 1161
This phase 1 study aimed to assess the tolerability, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of lenvatinib capsules in...
E7080 | Angiogenesis | Medicine & Public Health | Oncology | Cancer Research | Lenvatinib | Phase 1 | Safety | Pharmacology/Toxicology | Japanese | PLACEBO | ONCOLOGY | PHARMACOLOGY & PHARMACY | CANCER | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Nausea - chemically induced | Area Under Curve | Humans | Japan | Middle Aged | Male | Metabolic Clearance Rate | Treatment Outcome | Thrombocytopenia - chemically induced | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Quinolines - pharmacokinetics | Asian Continental Ancestry Group | Neoplasms - ethnology | Phenylurea Compounds - adverse effects | Adult | Female | Phenylurea Compounds - pharmacokinetics | Headache - chemically induced | Quinolines - adverse effects | Hypertension | Tyrosine | Medicine, Experimental | Medical research | Glycoproteins | Tumors | Index Medicus | Original
E7080 | Angiogenesis | Medicine & Public Health | Oncology | Cancer Research | Lenvatinib | Phase 1 | Safety | Pharmacology/Toxicology | Japanese | PLACEBO | ONCOLOGY | PHARMACOLOGY & PHARMACY | CANCER | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Nausea - chemically induced | Area Under Curve | Humans | Japan | Middle Aged | Male | Metabolic Clearance Rate | Treatment Outcome | Thrombocytopenia - chemically induced | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Quinolines - pharmacokinetics | Asian Continental Ancestry Group | Neoplasms - ethnology | Phenylurea Compounds - adverse effects | Adult | Female | Phenylurea Compounds - pharmacokinetics | Headache - chemically induced | Quinolines - adverse effects | Hypertension | Tyrosine | Medicine, Experimental | Medical research | Glycoproteins | Tumors | Index Medicus | Original
Journal Article
Journal of Occupational and Environmental Medicine, ISSN 1076-2752, 12/2019, Volume 61, Issue 12, pp. e523 - e527
OBJECTIVE:We aimed to evaluate the convergent validity and responsiveness of the work functioning impairment scale (WFun) in patients with depression, a major...
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 03/2017, Volume 7, p. 25
Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated...
Clinical trial | Anaplastic thyroid cancer | Lenvatinib | Phase 2 | Tyrosine kinase inhibitor | Care and treatment | Thyroid cancer | Health aspects | Cancer
Clinical trial | Anaplastic thyroid cancer | Lenvatinib | Phase 2 | Tyrosine kinase inhibitor | Care and treatment | Thyroid cancer | Health aspects | Cancer
Journal Article
International Heart Journal, ISSN 1349-2365, 2018
A 31-year-old man was admitted to our hospital with atrial tachycardia and cardiogenic shock. He had been diagnosed with hereditary spherocytosis (HS) during...
Heart failure | Cardiogenic shock | Atrial tachycardia
Heart failure | Cardiogenic shock | Atrial tachycardia
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 6088 - 6088
Journal Article
International heart journal, 03/2018, Volume 59, Issue 2, p. 427
A 31-year-old man was admitted to our hospital with atrial tachycardia and cardiogenic shock. He had been diagnosed with hereditary spherocytosis (HS) during...
Hemochromatosis - complications | Humans | Fatal Outcome | Adult | Male | Heart Failure - etiology | Spherocytosis, Hereditary - complications
Hemochromatosis - complications | Humans | Fatal Outcome | Adult | Male | Heart Failure - etiology | Spherocytosis, Hereditary - complications
Journal Article
Circulation Journal, ISSN 1346-9843, 2011, Volume 75, Issue 6, pp. 1493 - 1505
Background: Atorvastatin, rosuvastatin and pitavastatin are available for intensive, aggressive low-density lipoprotein cholesterol (LDL-C)-lowering therapy in...
Atorvastatin | Pitavastatin | Efficacy | Rosuvastatin | Safety | CAPILLARY ISOTACHOPHORESIS | MULTICENTER | CARDIAC & CARDIOVASCULAR SYSTEMS | HYPERLIPIDEMIA | ATHEROSCLEROSIS | SUBFRACTIONS | HYPERCHOLESTEROLEMIC PATIENTS | PHARMACOKINETICS | DISEASE | INTRAVASCULAR ULTRASOUND | STATIN TREATMENT | Prospective Studies | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Hypercholesterolemia - drug therapy | Patient Selection | Time Factors | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Hypercholesterolemia - blood | Japan | Rosuvastatin Calcium | Treatment Outcome | Biomarkers - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Analysis of Variance | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects
Atorvastatin | Pitavastatin | Efficacy | Rosuvastatin | Safety | CAPILLARY ISOTACHOPHORESIS | MULTICENTER | CARDIAC & CARDIOVASCULAR SYSTEMS | HYPERLIPIDEMIA | ATHEROSCLEROSIS | SUBFRACTIONS | HYPERCHOLESTEROLEMIC PATIENTS | PHARMACOKINETICS | DISEASE | INTRAVASCULAR ULTRASOUND | STATIN TREATMENT | Prospective Studies | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Hypercholesterolemia - drug therapy | Patient Selection | Time Factors | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Hypercholesterolemia - blood | Japan | Rosuvastatin Calcium | Treatment Outcome | Biomarkers - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Analysis of Variance | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects
Journal Article
12.
Full Text
Factors Associated with Variation in Utility Scores among Patients with Prostate Cancer
Value in Health, ISSN 1098-3015, 2008, Volume 11, Issue 7, pp. 1190 - 1193
Abstract Objective We aimed to assess the effects of age, comorbidity, and disease-specific functions on utility scores derived from three methods on prostate...
Internal Medicine | disease-specific functions | quality of life | utilities | prostatic neoplasms | disease‐specific functions | Utilities | Disease-specific functions | Prostatic neoplasms | Quality of life | PREFERENCES | MEN | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | OUTCOMES | HEALTH STATES | Health Surveys | Humans | Middle Aged | Intestinal Diseases - psychology | Aged, 80 and over | Quality of Life | Male | Aged | Prostatic Neoplasms - complications | Prostatic Neoplasms - psychology | Intestinal Diseases - etiology | Prostate cancer | Cancer patients | Electric utilities
Internal Medicine | disease-specific functions | quality of life | utilities | prostatic neoplasms | disease‐specific functions | Utilities | Disease-specific functions | Prostatic neoplasms | Quality of life | PREFERENCES | MEN | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | OUTCOMES | HEALTH STATES | Health Surveys | Humans | Middle Aged | Intestinal Diseases - psychology | Aged, 80 and over | Quality of Life | Male | Aged | Prostatic Neoplasms - complications | Prostatic Neoplasms - psychology | Intestinal Diseases - etiology | Prostate cancer | Cancer patients | Electric utilities
Journal Article
The Cleft Palate-Craniofacial Journal, ISSN 1055-6656, 7/2007, Volume 44, Issue 4, pp. 434 - 443
Objective: To evaluate the dental arch relationships of Japanese children with complete unilateral cleft lip and palate (UCLP) and to examine the 5-year-olds’...
Occlusal outcome | 5-year-olds' index | Cephalometrics | Model analysis | Cleft lip and palate | Dental arch relationship | Cephalometry - methods | Humans | Mandible - pathology | Cleft Palate - surgery | Child, Preschool | Male | Treatment Outcome | Dental Models | Radiography | Asian Continental Ancestry Group | Dental Arch - pathology | Epidemiologic Methods | Malocclusion - pathology | Sex Factors | Head - diagnostic imaging | Female | Maxilla - pathology | Cleft Lip - surgery | Birth defects | Deformities | Mouth | Children & youth
Occlusal outcome | 5-year-olds' index | Cephalometrics | Model analysis | Cleft lip and palate | Dental arch relationship | Cephalometry - methods | Humans | Mandible - pathology | Cleft Palate - surgery | Child, Preschool | Male | Treatment Outcome | Dental Models | Radiography | Asian Continental Ancestry Group | Dental Arch - pathology | Epidemiologic Methods | Malocclusion - pathology | Sex Factors | Head - diagnostic imaging | Female | Maxilla - pathology | Cleft Lip - surgery | Birth defects | Deformities | Mouth | Children & youth
Journal Article
Electrical Engineering in Japan, ISSN 0424-7760, 03/2002, Volume 138, Issue 4, pp. 42 - 49
The production of nonequilibrium plasma and the fluid flow with the MHD interaction are examined experimentally with a shock‐tube driven disk channel with no...
total pressure loss | disk MHD channel | nonequilibrium plasma | MHD interaction | magnetohydrodynamics | Nonequilibrium plasma | Magnetohydrodynamics | Total pressure loss | Disk MHD channel | ENGINEERING, ELECTRICAL & ELECTRONIC
total pressure loss | disk MHD channel | nonequilibrium plasma | MHD interaction | magnetohydrodynamics | Nonequilibrium plasma | Magnetohydrodynamics | Total pressure loss | Disk MHD channel | ENGINEERING, ELECTRICAL & ELECTRONIC
Journal Article
08/2006
PROBLEM TO BE SOLVED: To provide an elevator control device and an elevator control method, having no risk of declining service due to a feeling of distrust...
ELEVATORS | TRANSPORTING | HOISTING | ESCALATORS OR MOVING WALKWAYS | LIFTING | PERFORMING OPERATIONS | HAULING
ELEVATORS | TRANSPORTING | HOISTING | ESCALATORS OR MOVING WALKWAYS | LIFTING | PERFORMING OPERATIONS | HAULING
Patent
01/2005, 7
PROBLEM TO BE SOLVED: To provide a rail wire tie which is easy in transportation, assembly and removal, securely clamps a rail and stably applies prescribed...
TRANSPORTING | MACHINE TOOLS | WORKING BY LASER BEAM | CLADDING OR PLATING BY SOLDERING OR WELDING | METAL-WORKING NOT OTHERWISE PROVIDED FOR | WELDING | SOLDERING OR UNSOLDERING | CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING | PERFORMING OPERATIONS
TRANSPORTING | MACHINE TOOLS | WORKING BY LASER BEAM | CLADDING OR PLATING BY SOLDERING OR WELDING | METAL-WORKING NOT OTHERWISE PROVIDED FOR | WELDING | SOLDERING OR UNSOLDERING | CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING | PERFORMING OPERATIONS
Patent
06/1997, 6
PROBLEM TO BE SOLVED: To provide a camera monitor, which can operate lighting so that a part to be observed is excellently observed, a printed-board inspecting...
MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS | TESTING STATIC OR DYNAMIC BALANCE OF MACHINES ORSTRUCTURES | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES | MEASURING | TESTING STRUCTURES OR APPARATUS NOT OTHERWISE PROVIDED FOR | TESTING | ELECTRIC COMMUNICATION TECHNIQUE | CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS | PHYSICS | ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR | PICTORIAL COMMUNICATION, e.g. TELEVISION | ELECTRICITY | PRINTED CIRCUITS
MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS | TESTING STATIC OR DYNAMIC BALANCE OF MACHINES ORSTRUCTURES | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES | MEASURING | TESTING STRUCTURES OR APPARATUS NOT OTHERWISE PROVIDED FOR | TESTING | ELECTRIC COMMUNICATION TECHNIQUE | CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS | PHYSICS | ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR | PICTORIAL COMMUNICATION, e.g. TELEVISION | ELECTRICITY | PRINTED CIRCUITS
Patent
09/1996, 6
PURPOSE: To execute a centrifugal separation processing quickly and efficiently. CONSTITUTION: Eight holding parts 44 of a centrifugal separation means 40 are...
TRANSPORTING | TESTING | CENTRIFUGES | CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL ORCHEMICAL PROCESSES | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES | MEASURING | PHYSICS | PERFORMING OPERATIONS
TRANSPORTING | TESTING | CENTRIFUGES | CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL ORCHEMICAL PROCESSES | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES | MEASURING | PHYSICS | PERFORMING OPERATIONS
Patent
07/1990
PURPOSE:To eliminate the positional error of the center of curvature of a polishing bowl and the body to be worked and to finish in a highly accurate spherical...
TRANSPORTING | MACHINE TOOLS | METAL-WORKING NOT OTHERWISE PROVIDED FOR | DETAILS, COMPONENTS, OR ACCESSORIES FOR MACHINE TOOLS, e.g.ARRANGEMENTS FOR COPYING OR CONTROLLING | COMBINATIONS OR ASSOCIATIONS OF METAL-WORKING MACHINES, NOTDIRECTED TO A PARTICULAR RESULT | MACHINE TOOLS IN GENERAL CHARACTERISED BY THE CONSTRUCTION OFPARTICULAR DETAILS OR COMPONENTS | PERFORMING OPERATIONS
TRANSPORTING | MACHINE TOOLS | METAL-WORKING NOT OTHERWISE PROVIDED FOR | DETAILS, COMPONENTS, OR ACCESSORIES FOR MACHINE TOOLS, e.g.ARRANGEMENTS FOR COPYING OR CONTROLLING | COMBINATIONS OR ASSOCIATIONS OF METAL-WORKING MACHINES, NOTDIRECTED TO A PARTICULAR RESULT | MACHINE TOOLS IN GENERAL CHARACTERISED BY THE CONSTRUCTION OFPARTICULAR DETAILS OR COMPONENTS | PERFORMING OPERATIONS
Patent
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.